[A NEW TRANSITION PROGRAM FOR KIDNEY TRANSPLANTED YOUNG ADULTS FROM PEDIATRIC TO ADULT CARE SERVICES].

Background: Transition from pediatric to adult care services is a complex process, carrying medical, psychosocial and emotional issues. It is known that, during this period, patients may drop-out from follow-up, lose their adherence and suffer from psychosocial complications. This period is prone to rejection of the transplanted kidney.

Serologic response to COVID-19 infection or vaccination in pediatric kidney transplant recipients compared to healthy children.

Background: Differences in serologic response to COVID-19 infection or vaccination were reported in adult kidney transplant recipients (KTR) compared to non-immunocompromised patients. This study aims to compare the serologic response of naturally infected or vaccinated pediatric KTR to that of controls.

Methods: Thirty-eight KTR and 42 healthy children were included; aged ≤18 years, with a previously confirmed COVID-19 infection or post COVID-19 vaccination.

Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.

Background: Initial reports in adult kidney transplant recipients (KTR) indicate low immunogenicity after 2 doses of the BNT162b2 COVID-19 mRNA vaccine. We describe the immunogenicity of this vaccine compared to the serologic response in naturally infected COVID-19 positive adolescent and young adult KTR.

Methods: For this prospective observational study, the study group included 38 KTR who received 2 doses of the tested vaccine, and the control group included 14 KTR who had a previous polymerase chain reaction-confirmed COVID-19 infection.

Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Background: Decreased production of erythropoietin (EPO) is a major cause of anemia associated with chronic kidney disease (CKD). Treatment with recombinant human EPO (rHuEPO) improves patients' quality of life and survival; however, there is a marked variability in response to rHuEPO. At present, no available laboratory test is capable of evaluating responsiveness to EPO treatment.